News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Agenus (Formerly known as Antigenics Inc. - New York) (AGEN)’ Prophage Vaccine For Glioma Hailed As A "Very Promising Therapy" In An Editorial Published In The Journal Neuro-Oncology


1/21/2014 9:11:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme (GBM) were hailed as ‘exciting’ and a ‘very promising therapy’ in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES